- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.11. | FluoGuide A/S Publishes Interim Report Q3 2025 | 226 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 27, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO) today releases its results for the period 1 January - 30 September 2025. The Q3 report is... ► Artikel lesen | |
| 25.11. | FluoGuide A/S: FluoGuide Signs Collaboration Agreement with ZEISS | 278 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 25, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 25 November 2025 - FluoGuide A/S, a biotech company specializing in precision cancer surgery, announces... ► Artikel lesen | |
| 24.11. | Minutes from Extraordinary General Meeting in FluoGuide A/S | 210 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company" held an extraordinary general meeting on 24 November 2025.To the shareholders of FluoGuide... ► Artikel lesen | |
| FLUOGUIDE Aktie jetzt für 0€ handeln | |||||
| 24.11. | Invitation to FluoGuide A/S Webcast on 27 November 2025 | 228 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025.The following event will take place... ► Artikel lesen | |
| 05.11. | FluoGuide A/S: FluoGuide Strengthens Leadership to Advance Clinical Program and Regulatory Approval Strategy | 283 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces changes to both its... ► Artikel lesen | |
| 05.11. | FluoGuide A/S: FluoGuide Convenes an Extraordinary General Meeting | 241 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") hereby invites shareholders to participate in an extraordinary general meeting to be... ► Artikel lesen | |
| 03.11. | FluoGuide A/S Issue Warrants to Board Members, Executive Management and Employees | 269 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 3, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces that it has issued 199,000 warrants to members of the board directors, members... ► Artikel lesen | |
| 03.11. | FluoGuide A/S Completes Directed Share Issue of SEK 104 Million | 298 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER... ► Artikel lesen | |
| 03.11. | FluoGuide A/S Intends to Carry Out a Directed Share Issue of Approximately SEK 100 Million | 257 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER... ► Artikel lesen | |
| 28.10. | FluoGuide A/S: FluoGuide in Advanced Negotiations on Collaboration Agreement with a World Leading Medical Technology Company | 169 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / October 28, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company specializing in precision cancer surgery, announces to be in advanced... ► Artikel lesen | |
| 16.09. | FluoGuide A/S: FluoGuide Receives Positive FDA Feedback on FG001 in High-Grade Glioma | 255 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / September 16, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") received positive feedback and alignment with the FDA at a pre-IND consultation on its U.S. clinical... ► Artikel lesen | |
| 28.08. | FluoGuide A/S Publishes Interim Report H1 2025 | 210 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / August 28, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 28 August 2025 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period... ► Artikel lesen | |
| 22.08. | Invitation to FluoGuide A/S Webcast on 28 August 2025 | 272 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / August 22, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q2 2025 on Thursday 28 August 2025.The following event will take place later... ► Artikel lesen | |
| 21.07. | FluoGuide A/S: FluoGuide Enters Collaboration with Global MedTech Company Olympus | 512 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / July 21, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces a collaboration with... ► Artikel lesen | |
| 03.07. | FluoGuide A/S: Update on 2025 Outlook and Company progress | 303 | GlobeNewswire (Europe) | Copenhagen, Denmark, 3 July 2025 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an update on the 2025 Outlook... ► Artikel lesen | |
| 10.06. | FluoGuide A/S: FG001 clinical data in High-Grade Glioma is now published in Neurosurgery | 618 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / June 10, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision... ► Artikel lesen | |
| 28.05. | FluoGuide A/S: FluoGuide A/S publishes interim report for the period January - March 2025 - On track - first patients enrolled in CT-005 | 229 | GlobeNewswire (Europe) | Copenhagen, Denmark, 28 May 2025 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 31 March 2025. The Q1 report is available as an attached document... ► Artikel lesen | |
| 15.04. | FluoGuide A/S: FluoGuide includes first patient in phase II trial of FG001 for head and neck cancer | 232 | GlobeNewswire (Europe) | Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, is pleased to announce the inclusion of the first patient in its phase... ► Artikel lesen | |
| 27.03. | Minutes from Annual General Meeting in FluoGuide A/S | 345 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 27, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company" held its annual general meeting on 27 March 2025.To the shareholders of FluoGuide A/S.The... ► Artikel lesen | |
| 12.03. | Notice of Annual General Meeting in FluoGuide A/S | 405 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / March 12, 2025 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39 29 64... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BETA BIONICS | 31,690 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 38,000 | 0,00 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 20,200 | 0,00 % | Alignment Healthcare, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| HEARTFLOW | 31,250 | 0,00 % | Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Israel Englander, Viking Global, Point72 Asset Management, Heartflow Inc (HTFL), Teva Pharmaceutical Industries Ltd (TEVA), and More | ||
| PRIVIA HEALTH GROUP | 24,020 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| PROGYNY | 26,970 | 0,00 % | Progyny, Inc. - 8-K, Current Report | ||
| PROCEPT BIOROBOTICS | 34,250 | 0,00 % | Promising Growth Forecasts Leading to Analysts' Optimism for Procept Biorobotics (PRCT) | ||
| ADAPTHEALTH | 10,290 | 0,00 % | AdaptHealth: Strategische Expansion und Technologie-Investitionen als Wachstumstreiber | ||
| FRESENIUS MEDICAL CARE | 40,840 | +0,10 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,670 | -0,16 % | BERNSTEIN RESEARCH stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Siemens Healthineers mit "Outperform" und einem Kursziel von 52,90 Euro in die Bewertung wieder aufgenommen. Nach einem für die... ► Artikel lesen | |
| FRESENIUS | 48,660 | +0,23 % | DAX tiefer, China schwach: US-Arbeitsmarkt, Rheinmetall, Zalando, Fresenius, Nordex, Pfizer ... | Der DAX hat am Montag einen knappen Gewinn über die Ziellinie retten können. Aus dem Handel ging er mit einem Plus von 0,2 Prozent auf 24.229,91 Zählern. Zum Start in den Dienstag dürfte er zunächst... ► Artikel lesen | |
| GENEDX | 139,93 | 0,00 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| BILLIONTOONE | 96,29 | 0,00 % | BillionToOne, Inc.: BillionToOne Reports Third Quarter 2025 Results | MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| CASTLE BIOSCIENCES | 41,405 | +4,98 % | Castle Biosciences, Inc.: Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| LUMEXA IMAGING | 17,945 | 0,00 % | Lumexa Imaging Announces Pricing of Initial Public Offering | RALEIGH, N.C., Dec. 10, 2025 /PRNewswire/ -- Lumexa Imaging Holdings, Inc. ("Lumexa Imaging") announced today the pricing of its initial public offering of 25,000... ► Artikel lesen |
Das Unternehmen FLUOGUIDE A/S kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 3,100 Euro und damit +2,65 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLUOGUIDE A/S finden Sie auf Wallstreet Online.